Background
While antiretroviral therapy (ART) suppresses viremia to undetectable levels, people with HIV (PWH) show signs of chronic inflammation and immune dysfunction. Persistent viral antigenic stimulation may contribute to this phenomenon. In a cross-sectional study of ART-treated PWH with undetectable viremia, we recently reported that soluble gp120 (sgp120) was associated with markers of inflammation and immune dysfunction. However, the dynamics of plasmatic sgp120 levels, its association over time with inflammation, immune dysfunction and how this is affected by ART remains unclear.
Methods
To evaluate the dynamics of sgp120, we performed a longitudinal assessment of sgp120, anti-Env antibodies (Abs) including those targeting the CD4 binding site (CD4BS), and inflammatory markers associated with HIV-1 infection. We evaluated the association between sgp120 and CD4 count, IL-6, TNF-alpha and Galectin-9. Measures of associations were modelled using generalized least squares (GLS) linear regression with random effects (for repeated measures), with interaction terms between sgp120 levels and i) time period pre/post ART and ii) presence/absence of CD4BS Abs.
Results
We included 151 longitudinal samples from 23 PWH taken during primo-infection and up to 4 years post-ART initiation. The mean age of participants was 36.8, 95% were males. 21/23 participants had detectable levels of sgp120 for at least one timepoint. We observed that sgp120 was inversely associated with CD4 cell counts post-ART initiation (beta; -52.17 95%CI -84.64 to -19.70, p=0.002). We did not observe this association pre-ART initiation (beta; -27.10 95%CI -73.93 to 17.94, p=0.23, p-value for interaction 0.38). Of note, anti-CD4BS Abs, known to prevent sgp120-CD4 interaction, modulated the association between sgp120 and CD4 cell counts. Absence of anti-CD4BS Abs strengthened this association (beta; -57.38 95%CI -89.63 to -25.13, p<0.001) while their presence abrogated this association (beta; -14.86 95%CI -69.34 to 39.62, p=0.59, p-value for interaction 0.18). Among inflammatory markers, sgp120 was positively associated with Galectin-9 (log beta; 0.07 95%CI 0.00 to 0.13, p=0.025).
Conclusions
Our study suggests that sgp120 is associated with immune dysfunction in PWH and raises the intriguing possibility that therapeutic approaches targeting sgp120 could provide immune benefits and mitigate HIV-associated immune dysfunction in PWH.
Table or Figure
![]()